# **REMARKS**

### Status of Claims

Claims 1-9 were pending. Of these, claims 1, 2 and 8 had been withdrawn from consideration by the outstanding action, for being directed to non-elected subject matter. The remaining claims 3-7 and 9 had been rejected by the outstanding action.

This response cancels claims 1, 2 and 8 and adds new claims 10-12. (Claims 3-7 have been amended. Claim 7 which depended from claim 3 has been made independent.) Thus, claims 3-7, and 9-12 are now pending and under consideration.

# **Restriction and Election**

The applicants affirm that they have made the elections as described in the outstanding action. The election is now without traverse.

Claims 3-7 have been amended in a manner which is believed to exclude non-elected subject matter. As claim 9 depends from claim 3 it is believed that it, too, is directed only to elected subject matter. New claims 10-12 are believed to be directed only to elected subject matter.

#### Claim Rejections Under 35 USC 102(b)

Claims 3-7 and 9 stand rejected under 35 USC 102(b) as being anticipated by Lennox et al. (WO 99/07669).

The basis for rejection of claims 3-7 and 9 is believed to be overcome by the amendments of claims 3-7 made herein.

The action directs special attention to the compounds specifically disclosed by Lennox et al. (WO 99/07669) at page 13 lines 9-14 and 19-24. These are the compounds shown in the following table.


	Compounds Described By WO 99/07669 at Page 13			
Line	Nomenclature	Structure		
9	4-chloro-2-[3-(2,4-dichloro-phenyl)-acryloylamino]-benzozoic acid	CI CI HN COOH		
10	4-chloro-2-[3-(2,4-dichloro-phenyl)-2-methyl-acryloylamino]-benzozoic acid	CI HN CI		
11	4-chloro-3-[3-(2,4-dichloro-phenyl)-acryloylamino]-benzozoic acid	CI HN CI		

12	4-chloro-3-[3-(2,4-dichloro-phenyl)-2-methyl-acryloylamino]-benzozoic acid	Cl HN Cl
13	5-chloro-2-[3-(2,4-dichloro-phenyl)-acryloylamino]-benzozoicacid	CI HIN COOH CI
14	5-chloro-2-[3-(2,4-dichloro-phenyl)—2-methyl-acryloylamino]-benzozoic acid	Cl HN COOH Cl

15	2-[3-(3,4-dichloro-phenyl)-	Cl
	acryloylamino]-benzozoic	
	acid	CL
		, , , , , , , , , , , , , , , , , , ,
		HN
		COOH
16	2-[3-(3,4-dichloro-phenyl)-	Cl
	2-methyl-acryloylamino]-	
	benzozoic acid	CL
	benzozoic acid	
		HN
	•	COOH
17	3-[3-(3,4-dichloro-phenyl)-	Cl
	acryloylamino]-benzozoic	
		CL
	acid	
	·	
		HN
		COOL
		СООН

18	3-[3-(3,4-dichloro-phenyl)- 2-methyl-acryloylamino]- benzozoic acid	CI
		СООН
19	4-chloro-2-[3-(2,4-dichloro-phenyl)-acryloylamino]-benzozoicacid	CI CI CI COOH
20	4-chloro-2-[3-(2,4-dichloro-phenyl)—2-methyl-acryloylamino]-benzozoic acid	CI  O  HN  COOH

21	4-chloro-3-[3-(2,4-dichloro-phenyl)-acryloylamino]-benzozoicacid	CI
		СООН
22	4-chloro-3-[3-(2,4-dichloro-phenyl)—2-methyl-acryloylamino]-benzozoic acid	CI  HN  CI  COOH
23	5-chloro-2-[3-(2,4-dichloro-phenyl)-acryloylamino]-benzozoicacid	CI CI CI CI CI CI



Claims 3-7 as amended avoid anticipation because the definition of  $R_1$  is has been limited to  $C_{1-3}$ -alkyl and now excludes H. It will be observed that in none of the above-listed compounds described by WO 99/07669 is the moiety corresponding to  $R_1$  anything other than H.

It is urged that claim 9, as it depends from only claim 3, should be allowable to the extent that claim 3 is allowable.

# New Claims 10-12

New claim 10 is directed to a Markush group consisting of 24 specifically disclosed compounds. The compounds are those described by Examples 8, 10, 15, 16, 17, 20, 23, 26, 27, 38, 72, 77, 80, 81, 98, 116, 152, 155, 156, 157, 158, 159, 170 and 171. It is believed that all of these compounds fall within the scope of the election. New claims 11 and 12 are directed to the species described by Examples 16 and 17, respectively. It should be noted that the compounds of Examples 16 and 17 were also included in original claim 8, which has been cancelled.

### **Summary**

It is urged that the claims as amended are allowable and that the application as a whole is now in condition for allowance.

Respectfully submitted,

Alan Stempel

Attorney for Applicant(s)

Reg. No. 28,991

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368 Ridgefield, CT. 06877 Tel.: (203) 798-4868

- 26 -